{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:28Z","timestamp":1793064388736,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Radiotherapy is an established treatment for low-grade primary cutaneous B-cell lymphoma. Recommendations on its use differ internationally, which prompted our group to conduct this analysis. Twenty-two institutions participated in this international study. Patient eligibility required a diagnosis of limited (T1\/T2) primary cutaneous marginal zone or follicle center lymphoma treated with radiotherapy between 1995 and 2023. Data were collected retrospectively until February 2024 within the framework of the International Lymphoma Radiation Oncology Group. Overall, 535 patients were analyzed. Predominant locations were the head (40%) and trunk (36%). Radiotherapy had a median dose of 24 Gy in fractions of 2 Gy. Complete responses were observed in 91% at a median time of 3.6 months following radiotherapy. There was no statistically significant difference between treatments \u22644 Gy and &amp;gt;4 Gy for complete or overall response rates (P = .077 and P = .056, respectively). However, there was an inferior duration of local control with \u22644 Gy (5-year local control 73% \u00b1 12% vs 96% \u00b1 2%; P&amp;lt; .001). Radiation dose was the main prognostic factor in the univariate and multivariable Cox analysis; however, higher doses did not translate into an overall survival benefit. Toxicities rarely exceeded grade 2 but were more frequent in the &amp;gt;4 Gy group. Radiotherapy remains an effective treatment option for indolent skin lymphoma with low toxicity. High response rates are observed with low doses of \u22644 Gy. In comparison to conventional doses, these treatments have a shorter duration of local control but a favorable toxicity profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032050","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:17:20Z","timestamp":1773422240000},"page":"3051-3060","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-7013","authenticated-orcid":false,"given":"Michael","family":"Oertel","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany"},{"name":"2West German Cancer Center M\u00fcnster, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-9419","authenticated-orcid":false,"given":"Dennis","family":"G\u00f6rlich","sequence":"additional","affiliation":[{"name":"4Institute of Biostatistics and Clinical Research, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-3502","authenticated-orcid":false,"given":"Bjorn R.","family":"Thomas","sequence":"additional","affiliation":[{"name":"5St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7116-906X","authenticated-orcid":false,"given":"Van","family":"Sim","sequence":"additional","affiliation":[{"name":"5St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Johnstone","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Hashmi","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-3296","authenticated-orcid":false,"given":"Mario","family":"Levis","sequence":"additional","affiliation":[{"name":"9Department of Oncology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Ackerson","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hague","sequence":"additional","affiliation":[{"name":"11Department of Clinical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8262-6626","authenticated-orcid":false,"given":"Christopher R.","family":"Weil","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"12Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Plastaras","sequence":"additional","affiliation":[{"name":"13Department of Radiation Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Roos","sequence":"additional","affiliation":[{"name":"14Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide University School of Medicine, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[{"name":"15Department of Radiation Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"16Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"17Comprehensive Cancer Center Erlangen-European Metropolitan Area Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny Q.","family":"Fang","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ng","sequence":"additional","affiliation":[{"name":"18Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5795-9509","authenticated-orcid":false,"given":"Felix","family":"Bock","sequence":"additional","affiliation":[{"name":"19Department of Radiotherapy and Radiation Oncology, University Medical Center Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda D.","family":"Tseng","sequence":"additional","affiliation":[{"name":"20Department of Radiation Oncology, University of Washington, and Division of Radiation Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Linde","sequence":"additional","affiliation":[{"name":"21Department of Radiation Oncology, Cyberknife and Radiation Therapy, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Dunst","sequence":"additional","affiliation":[{"name":"22Department of Radiation Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Terezakis","sequence":"additional","affiliation":[{"name":"23Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Easwaran","sequence":"additional","affiliation":[{"name":"23Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-9853","authenticated-orcid":false,"given":"Jan C.","family":"Peeken","sequence":"additional","affiliation":[{"name":"24Department of Radiation Oncology, Technical University of Munich School of Medicine and Health, Technical University of Munich Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany"},{"name":"25Institute of Radiation Medicine, Helmholtz Zentrum M\u00fcnchen, Oberschlei\u00dfheim, Germany"},{"name":"26German Consortium for Translational Cancer Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wittig","sequence":"additional","affiliation":[{"name":"27Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany"},{"name":"28Department for Radiotherapy and Radiation Oncology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-6856","authenticated-orcid":false,"given":"Hong In","family":"Yoon","sequence":"additional","affiliation":[{"name":"29Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-4732","authenticated-orcid":false,"given":"Randa","family":"Tao","sequence":"additional","affiliation":[{"name":"12Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT"},{"name":"35Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Illidge","sequence":"additional","affiliation":[{"name":"30Manchester Academic Health Science Centre, Manchester Cancer Research Centre, University of Manchester, Cancer Research United Kingdom, The Christie National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[{"name":"9Department of Oncology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-5255","authenticated-orcid":false,"given":"Michael S.","family":"Binkley","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8723","authenticated-orcid":false,"given":"Belinda A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia"},{"name":"31Department of Clinical Pathology, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"5St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-7336","authenticated-orcid":false,"given":"Khaled","family":"Elsayad","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany"},{"name":"2West German Cancer Center M\u00fcnster, University Hospital M\u00fcnster, M\u00fcnster, Germany"},{"name":"32Marburg Ion-Beam Therapy Center, Department of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany"},{"name":"33Department of Radiotherapy and Radiation Oncology, Marburg University Hospital, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-0184","authenticated-orcid":false,"given":"Michael","family":"Storck","sequence":"additional","affiliation":[{"name":"34Institute of Medical Informatics, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-0194","authenticated-orcid":false,"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany"},{"name":"2West German Cancer Center M\u00fcnster, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2026061811220718700_bib1","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2026061811220718700_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2026061811220718700_bib3","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajh.26968","article-title":"Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2026061811220718700_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0360-3016(02)04199-8","article-title":"Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma","volume":"55","author":"Eich","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2026061811220718700_bib5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00277-018-3471-x","article-title":"Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience","volume":"97","author":"De Felice","year":"2018","journal-title":"Ann Hematol"},{"issue":"12","key":"2026061811220718700_bib6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"issue":"4","key":"2026061811220718700_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/10428194.2012.723707","article-title":"Radiotherapy in the management of localized primary cutaneous B-cell lymphoma","volume":"54","author":"Pashtan","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026061811220718700_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00066-018-1277-3","article-title":"Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas","volume":"194","author":"K\u00f6nig","year":"2018","journal-title":"Strahlenther Onkol"},{"issue":"20","key":"2026061811220718700_bib9","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026061811220718700_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00066-019-01538-2","article-title":"Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients","volume":"196","author":"Elsayad","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"2026061811220718700_bib11","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(24)00133-9","article-title":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","volume":"11","author":"Gunther","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"2026061811220718700_bib12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2024.2112","article-title":"Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: a phase 2 nonrandomized controlled trial","volume":"10","author":"Pinnix","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026061811220718700_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"issue":"4","key":"2026061811220718700_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026061811220718700_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026061811220718700_bib16","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clml.2021.10.009","article-title":"Characterization of primary and secondary cutaneous B-cell lymphomas: a population-based study of 4758 patients","volume":"22","author":"Leary","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026061811220718700_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2026061811220718700_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2017.07.053","article-title":"Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: a retrospective study","volume":"78","author":"Goyal","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2026061811220718700_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2015.1040012","article-title":"Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy","volume":"57","author":"Akhtari","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026061811220718700_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","article-title":"De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma","volume":"196","author":"Oertel","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"2026061811220718700_bib21","author":"National Institutes of Health National Cancer Institute","year":"2017"},{"issue":"2","key":"2026061811220718700_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026061811220718700_bib23","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"2026061811220718700_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 4","key":"2026061811220718700_bib25","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"2026061811220718700_bib26","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Primary Cutaneous Lymphomas Version 1.2025","year":"2024","journal-title":"NCCN"},{"key":"2026061811220718700_bib27","doi-asserted-by":"crossref","first-page":"115064","DOI":"10.1016\/j.ejca.2024.115064","article-title":"Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group","volume":"212","author":"Elsayad","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"2026061811220718700_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0360-3016(00)01383-3","article-title":"Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy","volume":"49","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2026061811220718700_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ijrobp.2024.11.011","article-title":"Real-world pattern-of-care analysis of primary cutaneous lymphomas radiation therapy among European Organisation for Research and Treatment of Cancer members","volume":"121","author":"Elsayad","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2026061811220718700_bib30","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026061811220718700_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrclinonc.2016.183","article-title":"Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy","volume":"14","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061811220718700_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2026061811220718700_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/fon.15.300","article-title":"Immunomodulatory effects of radiation: what is next for cancer therapy?","volume":"12","author":"Kumari","year":"2016","journal-title":"Future Oncol"},{"issue":"2","key":"2026061811220718700_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-019-02460-3","article-title":"Immune biological rationales for the design of combined radio- and immunotherapies","volume":"69","author":"Hader","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"28","key":"2026061811220718700_bib35","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026061811220718700_bib36","doi-asserted-by":"crossref","first-page":"adv00383","DOI":"10.2340\/00015555-3746","article-title":"Long-term therapeutic success of intravenous rituximab in 26 patients with indolent primary cutaneous B-cell lymphoma","volume":"101","author":"Porkert","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2026061811220718700_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bjd.19490","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma","volume":"184","author":"Chirico","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026061811220718700_bib38","doi-asserted-by":"crossref","first-page":"S1150","DOI":"10.1016\/S0167-8140(24)01701-8","article-title":"1270: modern radiotherapy for extended cutaneous lesions from lymphomas: results from a multi-center study","volume":"194","author":"Levis","year":"2024","journal-title":"Radiother Oncol"},{"issue":"5","key":"2026061811220718700_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/jdv.19799","article-title":"Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: a multicentric study in 100 patients","volume":"38","author":"Schirren","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061811220718700_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdin.2024.07.002","article-title":"Health-related quality of life in primary cutaneous B-cell lymphoma following local radiotherapy","volume":"17","author":"Heger","year":"2024","journal-title":"JAAD Int"},{"issue":"2","key":"2026061811220718700_bib41","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ijrobp.2024.07.110","article-title":"Defining the role of radiotherapy for indolent, primary cutaneous B-cell lymphoma \u2013 first results from a multicenter registry by the International Lymphoma Radiation Oncology Group (ILROG)","volume":"120","author":"Oertel","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3051\/2528261\/blood_bld-2025-032050-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3051\/2528261\/blood_bld-2025-032050-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:22:18Z","timestamp":1781796138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/25\/3051\/567182\/Radiotherapy-for-indolent-primary-cutaneous-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":41,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032050","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,18]]},"published":{"date-parts":[[2026,6,18]]}}}